How Long Does Enrollment Take? Timelines, Benchmarks, and What Slows You Down

Clinical trial enrollment typically takes 6 to 24 months, depending on the phase, therapeutic area, protocol complexity, and number of sites. Phase I first-in-human studies may enroll in a matter of weeks. Large Phase III trials in rare diseases can take 3–5 years. The median across all industry-sponsored trials falls somewhere around 12–18 months, but the median obscures a reality that most sponsors know firsthand: most trials run significantly behind their original enrollment projections.

Enrollment Timeline Benchmarks by Phase and Therapeutic Area

By Phase: Typical Enrollment Duration

• Phase I (healthy volunteers or small patient cohorts): 1–6 months

• Phase II (proof of concept, 50–300 patients): 6–18 months

• Phase III (pivotal, 300–3,000+ patients): 12–36 months

• Phase IV (post-market, large registry-type): 12–48 months

By Therapeutic Area (Phase II–III): Median Enrollment Duration

• Dermatology: 8–14 months

• Cardiovascular: 12–24 months

• Diabetes / Metabolic: 10–18 months

• Respiratory: 10–20 months

• Oncology: 18–36 months

• CNS / Psychiatry: 18–30 months

• Rare Disease: 24–60+ months

Benchmarks sourced from Tufts Center for the Study of Drug Development (CSDD) and ClinicalTrials.gov analysis.

The Enrollment Gap: Why Timelines Slip

The Tufts CSDD has consistently found that approximately 80% of clinical trials fail to meet their original enrollment deadline. The average delay is 6–12 months. For sponsors in competitive categories, that delay has direct commercial consequences.

What drives the gap between projected and actual enrollment timelines?

1. Overly Optimistic Site Projections

Sites routinely overestimate how many eligible patients they'll be able to enroll per month. This happens because:

• Investigators often assess their general patient population, not the subset who will meet I/E criteria

• Site coordinators underestimate the time required for screening, consenting, and scheduling

• Competing studies at the same site reduce available coordinator bandwidth

Industry benchmark: Sites typically enroll at 40–60% of their projected rate.

2. Slow Site Activation

Before a site can enroll its first patient, it must complete IRB/IEC approval, contract negotiation, and investigator training. This process routinely takes 4–8 months from site selection — and every month of activation delay is a month of zero enrollment.

3. High Screen Failure Rates

As covered in our screen failure guide, rates of 40–70% are common. If a site sees 20 potential patients per month but only 6 pass screening, the effective enrollment rate is a fraction of what the site roster would suggest.

4. Patient Dropout Before Enrollment

Patients who pass pre-screening may disengage before completing formal screening. Life circumstances, competing demands, protocol burden, or simply losing interest between contact and scheduled visit can reduce conversion rates significantly. Typical pre-screen to enrollment conversion rates are 15–35% for digitally-recruited patients.

5. Geographic Concentration

Many sponsors rely heavily on academic medical centers, which are geographically clustered. A study with 20 sites, all within 50 miles of major metro areas, excludes the majority of the eligible patient population by default.

6. Seasonal Patterns

Enrollment in many therapeutic areas has seasonal rhythm. Respiratory studies fill faster in fall/winter. Dermatology studies slow during summer. Pediatric studies pause around school calendar breaks. Failure to model seasonality leads to overly linear enrollment projections.

Enrollment Rate Modeling: How to Build a Realistic Projection

A credible enrollment projection should account for:

1. Site ramp-up time Sites rarely enroll at full capacity on Day 1. A typical ramp-up curve assumes 20–30% of full capacity in month 1, 50–70% in month 3, and full capacity by month 5–6.

2. Screen failure rate Total screened = target enrollment ÷ (1 − screen failure rate). This determines how many patients must enter formal screening to yield your target enrollment — which informs media and outreach requirements.

3. Pre-screen to screen conversion Not every patient who contacts a site or completes a pre-screener proceeds to formal screening. Conversion rates vary by disease area and recruitment channel.

4. Dropout and replacement Early dropout (before randomization) requires replacement. Planning for a 10–20% replacement buffer in enrollment targets is standard practice.

5. Site performance distribution High-enrollment sites ("hero sites") carry a disproportionate share of enrollment. A robust projection should model the distribution of site performance, not just the average.

What Accelerates Enrollment

Early and Continuous Patient Recruitment Investment

Recruitment that begins at or before site activation- building a pre-qualified patient pipeline before sites are ready to screen — compresses the timeline significantly. Waiting until all sites are active to begin recruitment is a costly delay.

Decentralized and Hybrid Approaches

Removing geographic barriers by accepting remote pre-screening, telemedicine visits, and home-based assessments expands the eligible population and reduces the time from first contact to enrollment.

Site Activation Support

Dedicated site activation resources - regulatory support, contract acceleration, and training programs — can cut average activation time by 30–50%.

Real-Time Enrollment Analytics

Dashboards that surface site-level enrollment rates, screen failure breakdowns, and referral conversion in real time allow rapid reallocation of resources. Sponsors who review enrollment data weekly are consistently faster than those reviewing monthly.

Contingency Site Planning

Identifying and partially activating backup sites before they're formally needed reduces the lag time when an underperforming site needs to be supplemented or replaced.

Red Flags That Enrollment Is Off Track

Enrollment delays are usually visible early, if you're watching the right signals:

• Site activation taking longer than 4 months on average

• Pre-screen to enrollment conversion below 20% without a known protocol-specific explanation

• Screen failure rate trending upward over the first 60 days of enrollment

• More than 30% of sites accounting for zero enrollments 60+ days post-activation

• Enrollment rate in the first quarter less than 60% of projection

Any of these patterns should trigger a formal enrollment strategy review, not a wait-and-see approach.

Key Takeaways

• Enrollment typically takes 6–24 months for Phase II–III trials; rare disease and CNS often take longer.

• ~80% of trials miss their original enrollment deadline, with delays averaging 6–12 months.

• The biggest drivers of delay are optimistic site projections, slow activation, high screen failure rates, and geographic concentration.

• Realistic enrollment modeling accounts for site ramp-up, screen failure, conversion rates, and dropout replacement.

• Proactive recruitment, real-time analytics, and decentralized strategies are the most reliable levers for accelerating timelines.